Understanding the dynamics of the pharmaceutical market using a social marketing framework

Purpose – The objectives of this paper are to describe the “affordable drugs movement” and present a social marketing framework to place major developments within a meaningful theoretical context.Design/methodology/approach – Specific examples are used to illustrate the framework and its utility in understanding the complexities of the pharmaceutical market. Methods to research the dynamics of the market are also presented.Findings – Provides referenced descriptions and examples of forces causing change within the pharmaceutical market. Classifies forces into six conditions influencing successful social movements: structural conduciveness, structural strains, growth of generalized beliefs, precipitating events, mobilization for action, and utilization of social control by opponents. Suggests social research methodologies to study the conditions in greater depth.Research limitations/implications – This is a descriptive framework that has not been validated for its use in the pharmaceutical market.Practical...

[1]  J. Abramson.  Overdosed America: The Broken Promise of American Medicine , 2004 .

[2]  Valéria Cavalcanti Rolla,et al.  On the Take: How Medicine's Complicity with Big Business Can Endanger Your Health , 2004 .

[3]  A. Fendrick,et al.  A benefit-based copay for prescription drugs: patient contribution based on total benefits, not drug acquisition cost. , 2001, The American journal of managed care.

[4]  G. Zaltman,et al.  Social marketing: an approach to planned social change. , 1971 .

[5]  T. Bodenheimer,et al.  Disease management in the American market , 2000, BMJ : British Medical Journal.

[6]  T. Bodenheimer,et al.  Uneasy alliance--clinical investigators and the pharmaceutical industry. , 2000, The New England journal of medicine.

[7]  C. Atim.  Social movements and health insurance: a critical evaluation of voluntary, non-profit insurance schemes with case studies from Ghana and Cameroon. , 1999, Social science & medicine.

[8]  N. Carroll.  How effectively do managed care organizations influence prescribing and dispensing decisions? , 2002, The American journal of managed care.

[9]  Merrill Goozner,et al.  The $800 Million Pill: The Truth behind the Cost of New Drugs , 2004 .

[10]  M. Dukes,et al.  Accountability of the pharmaceutical industry , 2002, The Lancet.

[11]  D P Sulmasy,et al.  The Effect of Pharmaceutical Benefits Managers: Is It Being Evaluated? , 1996, Annals of Internal Medicine.

[12]  B L Wolf,et al.  Drug samples: benefit or bait? , 1998, JAMA.

[13]  D. Holdford.  Using buzz marketing to promote ideas, services, and products. , 2004, Journal of the American Pharmacists Association : JAPhA.

[14]  J. Banaszak-Holl,et al.  A critical review of recent US market level health care strategy literature. , 2000, Social science & medicine.

[15]  R. Frank.  Government commitment and regulation of prescription drugs. , 2003, Health affairs.

[16]  J. Newhouse.  How much should Medicare pay for drugs? , 2004, Health affairs.

[17]  D. Blumenthal,et al.  The impact of a national prescription drug formulary on prices, market share, and spending: lessons for Medicare? , 2003, Health affairs.

[18]  A. Maynard,et al.  Dilemmas in regulation of the market for pharmaceuticals. , 2003, Health affairs.

[19]  R. Berenson,et al.  Are market forces strong enough to deliver efficient health care systems? Confidence is waning. , 2004, Health affairs.

[20]  J. Lenzer.  Scandals have eroded US public's confidence in drug industry , 2004, British medical journal.

[21]  Steven H. Landers,et al.  Health care lobbying in the United States. , 2004, The American journal of medicine.

[22]  Andrew Herxheimer,et al.  Relationships between the pharmaceutical industry and patients' organisations , 2003, BMJ : British Medical Journal.

[23]  Hugh Brooks,et al.  Merchandising Commodities and Citizenship on Television , 1951 .

[24]  Jeffrey S. Levin,et al.  Is self-care a social movement? , 1983, Social science & medicine.

[25]  A. Wazana,et al.  Physicians and the Pharmaceutical Industry , 2006 .

[26]  Jerry Avorn,et al.  Powerful Medicines: The Benefits, Risks, and Costs of Prescription Drugs , 2004 .

[27]  Barbara Mintzes,et al.  Outcomes-based drug coverage in British Columbia. , 2004, Health affairs.

[28]  Paul F. Lazarsfeld,et al.  Mass communication popular taste and organized social action. , 1948 .

[29]  J. D. Kleinke.  Access versus excess: value-based cost sharing for prescription drugs. , 2004, Health affairs.

[30]  J. Calfee,et al.  Pharmaceutical Price Controls and Patient Welfare , 2001, Annals of Internal Medicine.

[31]  A. Wazana,et al.  Physicians and the pharmaceutical industry: is a gift ever just a gift? , 2000, JAMA.

[32]  P. Kotler,et al.  The marketing of social causes: the first 10 years. , 1980, Journal of marketing.

[33]  Paul Jung,et al.  No free lunch. , 2002, Health affairs.

[34]  B. Djulbegovic,et al.  Pharmaceutical industry sponsorship and research outcome and quality: systematic review , 2003, BMJ : British Medical Journal.

[35]  Philip Kotler,et al.  What Consumerism Means to Marketers , 1972 .

[36]  A. Fendrick,et al.  Barriers to constraining health care cost growth. , 2004, Health affairs.

[37]  Trevor Jackson.  Are you being duped? , 2001, BMJ : British Medical Journal.

[38]  R. Eisenberg.  The shifting functional balance of patents and drug regulation. , 2001, Health affairs.

[39]  Using Content Analysis to Understand the Consumer Movement , 1989 .

[40]  M. Angell.  The Truth About the Drug Companies: How They Deceive Us and What to Do About It , 2004 .

[41]  C. Cowan,et al.  Health spending growth slows in 2003. , 2005, Health affairs.

[42]  A. Relman,et al.  Separating continuing medical education from pharmaceutical marketing. , 2001, JAMA.

[43]  D. Menon.  Pharmaceutical cost control in Canada: does it work? , 2001, Health affairs.